1. South Australian Health and Medical Research Institute, Division of Haematology and Centre for Cancer Biology, South Australia Pathology, University of Adelaide, Adelaide, Australia;
2. Princess Margaret Hospital, Leukemia Clinic, Blood and Marrow Transplant Centre, Apheresis Unit, Toronto, ON, Canada;
3. Universidade Federal do Rio de Janeiro, Department of Clinical Medicine, Rio de Janeiro, Brazil;
4. Hospital Clínic L'Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;
5. Universidade Federal do Paraná, Hospital de Clinicas, Curitiba, Paraná, Brazil;
6. Hospital Das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil;
7. Hospital das Clinicas, Faculdade de Medicina da Universidade de São Paulo, Hematology Department, São Paulo, Brazil;
8. Hematology Department, Alfred Hospital, Melbourne, Australia;
9. Laboratoire d'Hématologie, Centre Hospitalier Universitaire de Bordeaux and Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Biothérapies des Maladies Génétiques et Cancers, Inserm U1035, Université Bordeaux Ségalen, Bordeaux, France;
10. Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France;
11. Centre for Cancer Biology, South Australia Pathology, University of Adelaide, Adelaide, Australia;
12. Novartis Pharmaceuticals Corporation, East Hanover, NJ; and
13. McMaster University and Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada